APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Coagulation Factor Ⅷ for Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Coagulation Factor Ⅷ for Injection Market Outlook and Growth Opportunities 2026

31 December 2025190 pages

Choose your research edition.

Industry ResearchRecombinant Coagulation Factor Ⅷ for Injection Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Coagulation Factor Ⅷ for Injection Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Recombinant Coagulation Factor Ⅷ for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Coagulation Factor Ⅷ for Injection Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Coagulation Factor Ⅷ for Injection Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Recombinant Coagulation Factor Ⅷ for Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Coagulation Factor Ⅷ for Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Coagulation Factor Ⅷ for Injection market include GC Pharma, Novo Nordisk A/S, SinoCell Tech, Baxter, Bayer, Hualan Biological, Pfizer, Shanghai Raas Corp and Shanghai Xinxing Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Coagulation Factor Ⅷ for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Coagulation Factor Ⅷ for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Coagulation Factor Ⅷ for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Coagulation Factor Ⅷ for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Coagulation Factor Ⅷ for Injection Segment by Company

GC Pharma

Novo Nordisk A/S

SinoCell Tech

Baxter

Bayer

Hualan Biological

Pfizer

Shanghai Raas Corp

Shanghai Xinxing Medicine

Shandong Taibang Biological Products

Recombinant Coagulation Factor Ⅷ for Injection Segment by Type

250 IU/Bottle

500 IU/Bottle

1000 IU/Bottle

2000 IU/Bottle

Recombinant Coagulation Factor Ⅷ for Injection Segment by Application

Hospital

Clinic

Others

Recombinant Coagulation Factor Ⅷ for Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Recombinant Coagulation Factor Ⅷ for Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Coagulation Factor Ⅷ for Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Coagulation Factor Ⅷ for Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Coagulation Factor Ⅷ for Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Coagulation Factor Ⅷ for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Coagulation Factor Ⅷ for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Coagulation Factor Ⅷ for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Coagulation Factor Ⅷ for Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Coagulation Factor Ⅷ for Injection industry.

Chapter 3: Detailed analysis of Recombinant Coagulation Factor Ⅷ for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Coagulation Factor Ⅷ for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Coagulation Factor Ⅷ for Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Coagulation Factor Ⅷ for Injection Industry Trends Table 2. Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers Table 3. Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges Table 4. Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints Table 5. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Company (2021-2026) Table 7. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Company (Units) & (2021-2026) Table 8. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Coagulation Factor Ⅷ for Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Recombinant Coagulation Factor Ⅷ for Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Coagulation Factor Ⅷ for Injection Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Coagulation Factor Ⅷ for Injection Company, Product Type & Application Table 13. Global Recombinant Coagulation Factor Ⅷ for Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Coagulation Factor Ⅷ for Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 250 IU/Bottle Table 18. Significant Companies of 500 IU/Bottle Table 19. Significant Companies of 1000 IU/Bottle Table 20. Significant Companies of 2000 IU/Bottle Table 21. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 22. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Type (2021-2026) & (Units) Table 23. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Type (2027-2032) & (Units) Table 24. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Type (2021-2026) Table 25. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Type (2027-2032) Table 26. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type (2021-2026) Table 30. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 35. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Application (2021-2026) & (Units) Table 36. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Application (2027-2032) & (Units) Table 37. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Application (2021-2026) Table 38. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Application (2027-2032) Table 39. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application (2021-2026) Table 43. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application (2027-2032) Table 44. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 45. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2021-2026) & (Units) Table 46. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region (2021-2026) Table 47. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2027-2032) & (Units) Table 48. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region (2027-2032) Table 49. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Region (2021-2026) Table 52. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Region (2027-2032) Table 54. Global Recombinant Coagulation Factor Ⅷ for Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Recombinant Coagulation Factor Ⅷ for Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 57. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 59. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Country (2021-2026) Table 60. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 61. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Country (2027-2032) Table 62. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Market Share by Country (2021-2026) Table 64. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Market Share by Country (2027-2032) Table 66. GC Pharma Company Information Table 67. GC Pharma Business Overview Table 68. GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 70. GC Pharma Recent Development Table 71. Novo Nordisk A/S Company Information Table 72. Novo Nordisk A/S Business Overview Table 73. Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 75. Novo Nordisk A/S Recent Development Table 76. SinoCell Tech Company Information Table 77. SinoCell Tech Business Overview Table 78. SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 80. SinoCell Tech Recent Development Table 81. Baxter Company Information Table 82. Baxter Business Overview Table 83. Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 85. Baxter Recent Development Table 86. Bayer Company Information Table 87. Bayer Business Overview Table 88. Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 90. Bayer Recent Development Table 91. Hualan Biological Company Information Table 92. Hualan Biological Business Overview Table 93. Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 95. Hualan Biological Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 100. Pfizer Recent Development Table 101. Shanghai Raas Corp Company Information Table 102. Shanghai Raas Corp Business Overview Table 103. Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 105. Shanghai Raas Corp Recent Development Table 106. Shanghai Xinxing Medicine Company Information Table 107. Shanghai Xinxing Medicine Business Overview Table 108. Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 110. Shanghai Xinxing Medicine Recent Development Table 111. Shandong Taibang Biological Products Company Information Table 112. Shandong Taibang Biological Products Business Overview Table 113. Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 115. Shandong Taibang Biological Products Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Recombinant Coagulation Factor Ⅷ for Injection Distributors List Table 119. Recombinant Coagulation Factor Ⅷ for Injection Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Recombinant Coagulation Factor Ⅷ for Injection Product Image Figure 2. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Coagulation Factor Ⅷ for Injection Sales (2021-2032) & (Units) Figure 5. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Recombinant Coagulation Factor Ⅷ for Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 250 IU/Bottle Image Figure 10. 500 IU/Bottle Image Figure 11. 1000 IU/Bottle Image Figure 12. 2000 IU/Bottle Image Figure 13. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 14. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Type (2021-2032) Figure 16. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 23. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Application (2021-2032) Figure 25. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application (2021-2032) Figure 28. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 29. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032) & (US$ Million) Figure 33. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032) & (US$ Million) Figure 39. South America Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Recombinant Coagulation Factor Ⅷ for Injection Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Recombinant Coagulation Factor Ⅷ for Injection Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 250 IU/Bottle
  • 500 IU/Bottle
  • 1000 IU/Bottle
  • 2000 IU/Bottle
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • GC Pharma
  • Novo Nordisk A/S
  • SinoCell Tech
  • Baxter
  • Bayer
  • Hualan Biological
  • Pfizer
  • Shanghai Raas Corp
  • Shanghai Xinxing Medicine
  • Shandong Taibang Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Coagulation Factor Ⅷ for Injection Market Dynamics
  1. 2.1 Recombinant Coagulation Factor Ⅷ for Injection Industry Trends
  2. 2.2 Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers
  3. 2.3 Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges
  4. 2.4 Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints
3 Recombinant Coagulation Factor Ⅷ for Injection Market by Company
  1. 3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Coagulation Factor Ⅷ for Injection Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Coagulation Factor Ⅷ for Injection Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Coagulation Factor Ⅷ for Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Coagulation Factor Ⅷ for Injection Company Product Type and Application
  8. 3.8 Global Recombinant Coagulation Factor Ⅷ for Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Coagulation Factor Ⅷ for Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Coagulation Factor Ⅷ for Injection Market by Type
  1. 4.1 Recombinant Coagulation Factor Ⅷ for Injection Type Introduction
  2. 4.1.1 250 IU/Bottle
  3. 4.1.2 500 IU/Bottle
  4. 4.1.3 1000 IU/Bottle
  5. 4.1.4 2000 IU/Bottle
  6. 4.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Type
  7. 4.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Type
  11. 4.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Type (2021-2032)
  13. 4.3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type (2021-2032)
5 Recombinant Coagulation Factor Ⅷ for Injection Market by Application
  1. 5.1 Recombinant Coagulation Factor Ⅷ for Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Application
  6. 5.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Application
  10. 5.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application (2021-2032)
6 Recombinant Coagulation Factor Ⅷ for Injection Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Coagulation Factor Ⅷ for Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Country, 2025 VS 2032
7 Recombinant Coagulation Factor Ⅷ for Injection Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Coagulation Factor Ⅷ for Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Coagulation Factor Ⅷ for Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GC Pharma
  2. 8.1.1 GC Pharma Company Information
  3. 8.1.2 GC Pharma Business Overview
  4. 8.1.3 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  6. 8.1.5 GC Pharma Recent Developments
  7. 8.2 Novo Nordisk A/S
  8. 8.2.1 Novo Nordisk A/S Company Information
  9. 8.2.2 Novo Nordisk A/S Business Overview
  10. 8.2.3 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  12. 8.2.5 Novo Nordisk A/S Recent Developments
  13. 8.3 SinoCell Tech
  14. 8.3.1 SinoCell Tech Company Information
  15. 8.3.2 SinoCell Tech Business Overview
  16. 8.3.3 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  18. 8.3.5 SinoCell Tech Recent Developments
  19. 8.4 Baxter
  20. 8.4.1 Baxter Company Information
  21. 8.4.2 Baxter Business Overview
  22. 8.4.3 Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  24. 8.4.5 Baxter Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Hualan Biological
  32. 8.6.1 Hualan Biological Company Information
  33. 8.6.2 Hualan Biological Business Overview
  34. 8.6.3 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  36. 8.6.5 Hualan Biological Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Shanghai Raas Corp
  44. 8.8.1 Shanghai Raas Corp Company Information
  45. 8.8.2 Shanghai Raas Corp Business Overview
  46. 8.8.3 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  48. 8.8.5 Shanghai Raas Corp Recent Developments
  49. 8.9 Shanghai Xinxing Medicine
  50. 8.9.1 Shanghai Xinxing Medicine Company Information
  51. 8.9.2 Shanghai Xinxing Medicine Business Overview
  52. 8.9.3 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  54. 8.9.5 Shanghai Xinxing Medicine Recent Developments
  55. 8.10 Shandong Taibang Biological Products
  56. 8.10.1 Shandong Taibang Biological Products Company Information
  57. 8.10.2 Shandong Taibang Biological Products Business Overview
  58. 8.10.3 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  60. 8.10.5 Shandong Taibang Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Coagulation Factor Ⅷ for Injection Value Chain Analysis
  2. 9.1.1 Recombinant Coagulation Factor Ⅷ for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Coagulation Factor Ⅷ for Injection Sales Mode & Process
  6. 9.2 Recombinant Coagulation Factor Ⅷ for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Coagulation Factor Ⅷ for Injection Distributors
  9. 9.2.3 Recombinant Coagulation Factor Ⅷ for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst